HAIFA, Israel - Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR), a company specializing in cell-based technology, has announced the approval of a new patent that could significantly impact the agricultural technology (agtech) sector. The patent, issued by the Israel Patent Office, pertains to a system for 3D cultivation of plant cells and methods of use, which enables efficient cultivation of plant cells for various applications.
The company's immediate application of this technology is in the production of sustainable cell-based coffee, which claims to use 98% less water and 95% less growing area compared to traditional methods. The patent is part of Pluri's strategic vision to scale the production of cell-based products industrially, potentially tapping into a broad spectrum of market opportunities.
Pluri, which operates in the fields of regenerative medicine, food-tech, and agtech, sees this technology as a potential solution to challenges such as food scarcity and sustainable agriculture. The company's proprietary 3D bioreactor technology is said to be accurate, scalable, cost-effective, and consistent, which could be transformative for the industry.
The global cellular agriculture market, valued at $133 billion in 2021, is projected to grow to $515 billion by 2030. Pluri's CEO and President, Yaky Yanay, believes that the newly patented technology positions Pluri as a leader in cell expansion technology for the agtech industry and could be used for a wide range of plant cell products, including food, beverages, and medicine.
Pluri's robust intellectual property portfolio includes over 140 active and granted patents, reflecting its pioneering role in the agtech industry. The company aims to establish partnerships to leverage its 3D cell-based technology in industries that require effective mass cell production, as well as offering Contract Development and Manufacturing Organization (CDMO) services.
The information in this article is based on a press release statement from Pluri Inc. and does not include speculative statements or endorsements of the company's claims.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.